# Acute Application of Pegvisomant and Octreotide in Acromegaly

> **NCT00595140** · PHASE4 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 10 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** pegvisomant
- **DRUG:** combination with somatostatin analogue octreotide
- **DRUG:** combination with dopamine agonist cabergoline

## Key facts

- **NCT ID:** NCT00595140
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2008-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595140, "Acute Application of Pegvisomant and Octreotide in Acromegaly". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00595140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*